Amyotrophic lateral sclerosis (ALS) is a debilitating and incurable disease involving the loss of motor neurons and subsequent muscle atrophy. Genetic studies have implicated deficits in autophagy and/or mitophagy in the onset of the disease. Here we review recent progress in our understanding of the pathways for autophagy and mitophagy in neurons, and how these pathways may be affected by mutations in genes including DCTN1, OPTN, TBK1, VCP, and C9ORF72. We also discuss the implications of modulating autophagy in ALS, highlighting both the potential of the approach and the concerns raised by targeting this pathway as a therapeutic strategy in neurodegenerative disease.
Introduction
Initially described in the late 19th century by Charcot and Joffroy, our scientific understanding of the devastating neurodegenerative disease Amyotrophic lateral sclerosis (ALS) has progressed significantly, particularly through the identification of causative mutations for familial forms of the disease. Genetic studies have implicated key pathways involved in pathogenesis, including autophagy and mitophagy. However, this knowledge has not yet led to the development of effective therapeutic strategies, suggesting that there are still key gaps in our understanding of the underlying mechanisms. This review summarizes progress investigating neuronal autophagy and mitophagy, and how that knowledge contributes to our understanding of the pathobiology of ALS.
What is ALS?
ALS is a debilitating neuromuscular disease characterized by the progressive degeneration of motor neurons in the spinal cord and brain. Degeneration of these motor neurons leads to neuromuscular denervation, atrophy of voluntary skeletal muscles, and ultimately paralysis and death. The worldwide incidence of ALS is estimated at~5/ 100,000 (Chio et al., 2013) . Onset is usually age-dependent, although rare genetic forms may have a juvenile onset. Global estimates indicate that incidence peaks between the ages of 50 and 75 years (Chia et al., 2018) . Disease progression is usually rapid, leading to death within 3-5 years of initial onset. There is currently no cure for this fatal disease, and available therapeutic options show only limited effectiveness.
Approximately 10% of ALS cases are familial in origin, with the remainder sporadic and of unknown cause. Possible causative factors for sporadic ALS include environmental factors such as infectious disease, chronic neuroinflammation, injury or trauma, and toxin exposure. However, the major shared risk factor across both sporadic and familial forms is aging. Progress on genetic causes of ALS has been very rapid in recent years, with~30 different genes now implicated (Chia et al., 2018) . Surprisingly, these genes do not fit easily into a single cellular pathway, although some themes do emerge. For example, a number of ALS-associated genes encode RNA-binding proteins, including TDP43 and FUS, suggesting that alterations in ribostasis may contribute to pathogenesis. Alterations in proteostasis, mitochondrial function, cytoskeletal integrity and intracellular trafficking have also been implicated (Taylor et al., 2016) . Strikingly, several of the ALS-associated genes identified to date have been functionally implicated in autophagy and/or mitophagy, specifically the clearance of protein aggregates and/or damaged mitochondria. ALS genes known to function in autophagy include OPTN, TBK1, and SQSTM1. More broadly, proteins encoded by the genes C9ORF72, VCP, CHMP2B, VAPB, ALS2, and DCTN1 have all been implicated in vesicular trafficking and may affect autophagy either directly or indirectly. A central role for autophagy in ALS is well supported by the pathology of the disease, which commonly includes the accumulation of protein aggregates and swollen or dystrophic mitochondria in motor neurons of affected patients (Taylor et al., 2016) .
Here we review the two best characterized pathways for autophagy in neurons, axonal autophagy and mitophagy, and discuss the available evidence linking dysfunction in these pathways to the onset and progression of ALS. We also highlight a few of the many questions that https://doi.org/10.1016/j.nbd.2018.07.005 Received 6 February 2018; Received in revised form 19 June 2018; Accepted 4 July 2018
